Kuhn et al claim that clinical studies have shown that selegiline, an MAO-B inhibitor , is therapeutically beneficial in Parkinson's and Alzheimer's diseases. In the present paper they report that selegiline influences cytokine biosynthesis and they postulate that this may contribute to its putative neuroprotective properties. The jury is still out regarding whether selegiline really has therapeutic effects in AD so it is premature to draw conclusions regarding how its therapeutic effects are mediated.
Comments
Kuhn et al claim that clinical studies have shown that selegiline, an MAO-B inhibitor , is therapeutically beneficial in Parkinson's and Alzheimer's diseases. In the present paper they report that selegiline influences cytokine biosynthesis and they postulate that this may contribute to its putative neuroprotective properties. The jury is still out regarding whether selegiline really has therapeutic effects in AD so it is premature to draw conclusions regarding how its therapeutic effects are mediated.
Make a Comment
To make a comment you must login or register.